Sarepta's (SRPT) Exondys gets broad coverage from Cigna (CI) - Bloomberg

September 28, 2016 9:39 AM EDT

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Sarepta Therapeutics (NASDAQ: SRPT) muscular dystrphy drug gets broad coverage from Cigna Corp. (NYSE: CI), according to Bloomberg. Cigna is tacking studies of Sarepta's Exondys for future benefit.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Momentum Movers, Trader Talk

Add Your Comment